The team, led by researchers from the University of Technology Sydney in Australia, focussed on "mitochondrial uncouplers" - molecules that make cells burn energy less efficiently and release fuel as

Expert Dr. Salas-Whalen reveals that body composition testing, not just the number on your scale, is key to knowing whether GLP-1 weight-loss medications are right for you.

The same global food system that is fueling rising obesity rates is also accelerating climate change, according to a sweeping new scientific review.

Global pharma giants Eli Lilly and Novo Nordisk are scrambling to cement their lead in India's booming obesity drug market before cheaper generic versions hit shelves in March next year. Novo's strategy emphasizes price cuts and accelerated launches,

Whalen, M.D., author of the new book "Weightless," shared that the best way to determine the suitability of a GLP-1 is through body composition testing.

“Early intervention would be lifestyle change, and that can be extremely helpful, especially in younger adolescents who are in the middle of rapid growth in height due to pubertal onset,” she said.

Mortality rates are high in patients with type 1 diabetes, and overweight and obesity appear to be major factors, a speaker said during the World Congress on Insulin Resistance, Diabetes and Cardiovascular Disease.

WorldAtlas has released a list of the ten states with the highest obesity rates. Louisiana was listed as the third state with the highest obesity rate.

Host-Related Determinants of Immunotherapy Response in NSCLC may include obesity, sarcopenia, metabolic comorbidities, sex, and systemic inflammation, supporting better patient stratification and more personalized immune checkpoint inhibitor strategies.

Regulators approved the first-ever GLP-1 pill for treating obesity from Novo Nordisk. Alphabet will acquire data center company Intersect for $4.75 billion in cash and assume its debt. Instacart is ending its contentious AI-driven pricing tests.